Cell–cell transmission allows human T-lymphotropic virus 1 to circumvent tetherin restriction  by Ilinskaya, Anna et al.















y Dejournal homepage: www.elsevier.com/locate/yviroCell–cell transmission allows human T-lymphotropic virus 1
to circumvent tetherin restrictionAnna Ilinskaya, David Derse y, Shawn Hill, Gerald Princler, Gisela Heidecker n
HIV-Drug Resistance Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USAa r t i c l e i n f o
Article history:
Received 21 March 2012
Returned to author for revisions
19 September 2012
Accepted 19 November 2012





Virological synapse.22/$ - see front matter Published by Elsevier
x.doi.org/10.1016/j.virol.2012.11.012
viations: APC, antigen presenting cell; ATM, a
nzyme-linked immunosorbent assay; Env, en
atidylinositol; HAM/TSP, HTLV-1 associated m
esis; HIV, human immunodeﬁciency virus; H
otropic virus; IFN a, interferon a; IS, immun
aposi’s sarcoma herpes virus; MHC, major h
icrotubule organizing center; PBLs, periphe
ian immunodeﬁciency virus; TCR, T-cell rece
s; VS, virological synapse
esponding author.
ail addresses: ilinskaa@mail.nih.gov (A. Ilinsk
@mail.nih.gov (S. Hill), jerryprin@comcast.ne
e@mail.nih.gov, giselafh@me.com (G. Heideck
ceased.a b s t r a c t
Tetherin is part of the cellular innate immunity and impedes cell-free transmission of viruses that bud
from the plasma membrane by retaining them on the cell surface. Some viruses have evolved activities
in different proteins such as Vpu (HIV-1), K-protein (KSHV), Nef (SIV) or Env (HIV-2) to downregulate
tetherin and overcome its restriction. We found that chronically HTLV-1 infected T-cell lines express
eightfold more tetherin than uninfected transformed T-cell lines suggesting that tetherin expression is
not inhibited by the virus. We observed that even small amounts of exogenous tetherin caused the
retention of HTLV-1 on the cell surface and severely reduced cell-free infectivity of HTLV-1, but that
cell–cell transmission, which is more relevant for HTLV-1, was signiﬁcantly less decreased. However,
knock-down of tetherin expresssion resulted in a slight increase in cell–cell infection indicating that the
protein does not enhance this route of transmission.
Published by Elsevier Inc.Introduction
Many retroviruses achieve rapid dissemination through the
release of cell-free virus particles as well as by cell–cell contact
(Johnson and Huber, 2002; Jolly et al., 2004; Jolly and Sattentau,
2004; Mothes et al., 2010; Phillips, 1994; Sattentau, 2008). Releasing
large numbers of stable virions can improve the range and prob-
ability of successful transmission to a susceptible target cell through
blood, lymph, cerebrospinal and other bodily ﬂuids, but exposes the
virus to immune system surveillance and biophysical and kinetic
barriers (Sattentau, 2008). In contrast, cell–cell viral transmission is
limited to proximal cell contacts, but potentially beneﬁts the virus
by avoiding neutralization by the immune response that would
hinder the cell-free virus. Cell–cell transmission may also allow the
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er).and release to the region of contact. Additionally, accumulation of
viral proteins, in particular envelope (Env), in the limited area of
cell–cell contact could lead to interaction with receptors and
remodulation of the target cells to make viral transmission more
efﬁcient (Mothes et al., 2010).
Human T-lymphotropic virus 1 (HTLV-1) is the causative agent
of acute T-cell lymphoma (ATL) and HTLV-1 associated myelo-
pathy/tropical spastic paraparesis (HAM/TSP) (Gallo and Reitz,
1985; Gessain et al., 1985; Poiesz et al., 1980a, 1980b; Robert-
Guroff et al., 1985). HTLV-1 infects target cells primarily through
cell–cell contact (Igakura et al., 2003). HTLV-1 is capable of infecting
a wide range of cell types as the components of its receptor complex
(GLUT-1, neuropilin and heparin sulfate proteoglycans) are ubiqui-
tously expressed (Ghez et al., 2006; Jones et al., 2005; Manel et al.,
2005; Swainson et al., 2005), but T-lymphocytes are the major
reservoir of the virus in vivo. No viremia is found in HTLV-1–infected
patients in vivo, and although cell-free virus particles can be detected
in the supernatant of freshly cultured HTLV-infected-cells, only 1 in
105 to 1 in 106 of these virions appears to be infectious (Derse et al.,
2001; Fan et al., 1992; Majorovits et al., 2008; Nejmeddine and
Bangham, 2010). HTLV-1 infection with cell-free virus is inefﬁcient
in vitro (Mazurov et al., 2010) and infectious transmission between
individuals is known to require the presence of HTLV-infected
lymphocytes in breast milk, semen, or blood products. The precise
mechanism of cell–cell infection in vivo is unknown, but two types of
cell–cell transmission in vitro have been described.
Igakura et al. (2003) ﬁrst used immunoﬂuorescence micro-
scopy to visualize transmission of HTLV-1 via a cell–cell contact
they termed virological synapse (VS). The term was coined
Fig. 1. HTLV-1 does not down regulate tetherin. Western blot analysis of HEK293T
and HeLa cells transfected with 0.8 mg HTLV-1 plasmid pCMVHT1-M and 0.3 mg
plasmid expressing HIV-1 Vpu or empty vector plasmid. HEK293T cells were
additionally co-transfected with 0.3 mg of plasmid encoding WT tetherin. Blots
were probed with anti-p19MA mAb as described in Materials and Methods (these
mAbs are able to recognize unprocessed precursor of Gag (p55) (Heidecker et al.,
2004)).
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T-lymphocyte and the virus receptor on the target cell resembled
an immunological synapse (IS), which is induced by the interac-
tion between the major histocompatibility complex (MHC) on the
antigen presenting cell (APC) and the T-cell receptor (TCR) on the
T-cell. Even though different sets of molecules initiate the forma-
tion of VS and IS, both synapses have segregated microdomains of
talin and the microtubule organization center (MTOC) is oriented
toward cell–cell contact (Davis et al., 2003). However, the MTOC
of the producer cell reorients towards the VS (Igakura et al., 2003;
Barnard et al., 2005). This is in contrast to the reorganization of
the MTOC towards the clustered TCR in the target T-cell after IS
formation. This observation immediately suggested that HTLV-1
induced cytoskeletal polarization in order to transmit viral material
to the uninfected cell (Nejmeddine and Bangham, 2010).
Recently a new type of cell–cell transmission was described,
which is based on the observation that some viral particles are
stored after budding in the extracellular matrix of the producer cells,
which is formed by carbohydrate-rich components and linker
cellular proteins (Pais-Correia et al., 2010; Jones and Green, 2010;
Thoulouze and Alcover, 2011). These viral assemblies are transferred
to target cells during the interaction between infected and non-
infected T-lymphocytes and can be observed on the surface of the
cells in multiple sites, even quite distant from cell–cell contact. This
mode of transfer does not require any special remodeling in cells;
thus the infection can occur quite rapidly. Collagen, agrin, galectin-3,
and tetherin are some of the components that form the extracellular
matrix trapping the viral particles.
Tetherin is a cellular transmembrane protein with unusual
topology: both N- and C-terminal ends are anchored in the
membrane via a glycosyl-phosphatidylinositol (GPI) anchor and
conventional transmembrane domains, respectively (Kupzig et al.,
2003). The GPI-anchor is responsible for the enrichment of
tetherin in lipid rafts. Tetherin, which is also known as BST2 or
CD317, was originally identiﬁed and cloned in 1995, is expressed
on the surface of B-cells, T-cells, monocytes and macrophages,
and plasmocytoid dendritic cells (Evans et al., 2010; Ishikawa
et al., 1995). Tetherin has more recently been identiﬁed as part of
the innate antiviral defense mechanisms based on its ability to
tether human immunodeﬁciency virus (HIV)-1 and other viral
particles on the cell surface (Neil et al., 2008; Jouvenet et al.,
2009; Van Damme et al., 2008). Acting nonspeciﬁcally, tetherin
prevents the release of viral particles, keeping them attached to
the membrane of the infected cell (Jouvenet et al., 2009; Perez-
Caballero et al., 2009). The retained viral particles are fully formed
and mature, and are eventually endocytosed and degraded (Neil
et al., 2006). Viruses have evolved functions to counteract the tetherin
effect; for instance, for most HIV-1 strains the protein Vpu acts as a
tetherin antagonist (Strebel et al., 1988). The mechanism of anti-
tetherin activity of Vpu is not completely deﬁned. It is believed that
Vpu directly interacts with tetherin triggering downregulation from
the cell surface and further proteosomal or lysosomal degradation
(Douglas et al., 2009; Gofﬁnet et al., 2009; Iwabu et al., 2009; Rong
et al., 2009; Skasko et al., 2011). In other viruses the anti-tetherin
activity is carried out by other proteins: for most simian immuno-
deﬁciency virus (SIV) strains, the function resides in Nef, for HIV-2 in
Env, for Kaposi’s sarcoma herpes virus (KSHV) in K5 and for other SIV
species and Ebola virus in the glycoproteins (Jia et al., 2009;
Kaletsky et al., 2009; Le Tortorec and Neil, 2009; Mansouri et al.,
2009; Rong et al., 2009; Sauter et al., 2009).
The inhibitory effect of tetherin on the cell-free spread of
viruses is immediately apparent; however, the consequences for
cell–cell transmission in the context of the VS or viral assembly
models are not as clearly predictable. Early papers suggested that
Vpu is not necessary under conditions of cell-to-cell transmission
(Gummuluru et al., 2000; Hamm et al., 1999). More recent studiesinvestigating the effect of tetherin on cell–cell transmission of
HIV-1 have reported slight negative or positive effects (Casartelli
et al., 2010; Jolly et al., 2010; Kuhl et al., 2010).
In this paper, we investigated the inﬂuence of tetherin on
HTLV-1 transmission. We show that HTLV-1 does not have a
mechanism to downregulate tetherin from the cellular surface.
Indeed, we detected elevated levels of tetherin in chronically
HTLV-1-infected T-cell lines. We observed the colocalization of
tetherin and virus particles at the site of cell–cell contact, but
found that at low to intermediate concentrations tetherin did not
have a signiﬁcant effect (less than twofold) on cell–cell infection.
In contrast, cell-free transmission at these concentrations was
almost completely restricted. Silencing of tetherin slightly facili-
tated transmission of virus through the cell–cell contact. In our
opinion, HTLV-1 can spread without downregulating tetherin
from the cellular membrane by relying on clonal expansion of
infected cells and cell–cell transmission.Results
HTLV-1 particles are restricted by tetherin
In our ﬁrst experiment, we showed that HTLV-1 particles
encoded by a full length proviral construct are retained on 293T
cells when tetherin is coexpressed, as has also previously been
demonstrated by Jouvenet et al. (2009). This ﬁnding suggests that
HTLV-1, which has several accessory genes in addition to gag, pro,
pol and env, does not encode a function that is able to counteract
tetherin (Fig. 1). As was shown before (Jouvenet et al., 2009),
addition of an HIV-1 Vpu encoding plasmid to the transfection
mix resulted in the efﬁcient release of the virus. Similar experi-
ments performed in HeLa cells showed that the endogenous
tetherin did not prevent virus release completely, suggesting that
HTLV-1 can overcome lower level expression of tetherin to some
extent.
HTLV-1 infected cell lines express higher levels of tetherin than
noninfected CD4þ T-cell lines
To address the question whether HTLV-1 infection affects the
expression of tetherin, we compared the expression levels of tetherin
protein in seven chronically infected T-cell lines (HUT102, MT2, MS9,
MS68, C3669, C8166, Su68) and in four uninfected transformed T-cell
lines (Jurkat E6, CEM174, Molt4, H9), as well as in activated
uninfected peripheral blood lymphocytes (PBLs) by Western blot
analysis. We found that HTLV-1 expressing cells have on average
higher steady state levels of tetherin than primary activated PBL or
uninfected CD4þ T-cell lines (Fig. 2A). We determined the expression
of tetherin relative to that of tubulin by densitometry analysis and
found that the average expression level of tetherin (in arbitrary units)
in uninfected cells was 15.5712.3 (mean7standard deviation)
Fig. 2. Chronically HTLV-1 infected T-cells express higher levels of tetherin than
controls. (A) Western blot analysis of cell extracts of the indicated cell lines.
Samples were run in duplicate on two gels and blots were probed either with
rabbit anti-tetherin or with mouse monoclonal anti-tubulin. The amount of
tetherin relative to the amount of tubulin in each sample was determined by
densitometry and graphed and the averages (arithmetic means) and standard
deviations for uninfected and infected samples are shown. The difference between
the two sample sets is signiﬁcant (P¼0.001 (Student’s T-test, single tailed,
different variances)). (B) Comparison of tetherin RNA expression in a subset of
the panel of cell lines used in (A). polyA RNA was isolated from the indicated cell
lines and RT-qPCR measurements were performed for tetherin and GAPDH
sequences. The graph (aligned to the one in A for comparison) shows the number
of tetherin RNAs/1000 GAPDH RNAs. No signiﬁcant ampliﬁcation was observed
without reverse transcription. The averages and standard deviations for the
infected and uninfected cells are given, and the difference in tetherin RNA
expression between the two sets is signiﬁcant (P¼0.015).
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between infected and uninfected cells was signiﬁcant (P¼0.001) as
determined by single-tailed Student’s T-test (different variances). The
higher total expression was also reﬂected in higher cell surface
exposure of tetherin on infected cells as determined by FACS analysis
(data not shown).
The enhanced expression of tetherin protein in infected cells
correlated with higher levels of tetherin RNA. RT-qPCR analysis of
the number of tetherin RNA molecules relative to the number of
GAPDH RNAs also revealed a signiﬁcant difference (P¼0.015); the
average RNA level in six infected lines (MT2, MS9, MS68, C3669,C8166, Su68) was 49726 molecules tetherin/1000 molecules
GADPH while in uninfected samples (act. PBL, H9, CEM174,
Molt4) the average level was 12.278.2 (Fig. 2B). The numbers
given here are from one of several independent experiments with
similar results. These ﬁndings support the notion that HTLV-1 did
not evolve the means to downregulate tetherin, but that tetherin
levels are elevated even in the absence of exogenous interferon.
Tetherin severely decreases cell-free but not cell–cell transmission
of HTLV-1
The previous sets of experiments predict that tetherin should
restrict HTLV-1 cell-free infection, while the effect on cell–cell
transmission cannot be easily anticipated. We used the recently
developed HTLV-1 replication dependent reporter system to
measure cell–cell transmission (Mazurov et al., 2010). The repor-
ter construct pCMVRU5-inluc is based on similar vectors devel-
oped to study the transmission of endogenous viruses and
retrotransposons (Curcio and Garﬁnkel, 1991; Heidmann and
Heidmann, 1991; Moran et al., 1996) (Fig. 3A). pCMVRU5-inluc
carries all the necessary cis acting elements of HTLV-1, but most
of the coding sequences have been replaced by a ﬁreﬂy luciferase
(luc) expression cassette inserted in anti-sense orientation into
the retroviral transcription unit. The retroviral transcript vector
contains an intron located in the luc gene, in such a way that it
can be spliced from the viral transcript but disrupts the open
reading frame on the luc RNA. Thus, luciferase is only expressed
after the retroviral vector transcript has been spliced, packaged
with components provided by the cotransfected packaging con-
struct, transferred to a target cell, reverse transcribed, integrated
and the now uninterrupted luc gene has been transcribed. We
ﬁrst wanted to determine the effect of tetherin on overall
transmission of HTLV-1 in HEK293T cells. We cotransfected the
pCMVRU5-inluc plasmid, the full-length pCMVHT-1M packaging
construct and increasing amounts of the myc-tetherin expression
construct into HEK293T cells and incubated the cells 48 h prior to
lysis and determination of luciferase activity. The infectivity in
this experiment is a combination of cell-free as well as cell–cell
transmission and showed a gradual decrease from 80 to 35% of
the no tetherin control sample with increasing amounts of
tetherin (Fig. 3B, black line). To determine the effect of tetherin
on the cell-free transmission in these cultures, we harvested the
supernatants just prior to lysis and transferred them to fresh
HEK293T cells, which were then incubated for 48 h. Even the
smallest amount of tetherin drastically decreased the amount of
infectious virus in the supernatant resulting in a more than
tenfold reduction of luciferase activity in the infected culture
compared to the no tetherin control (Fig. 3B, cell-free - gray line).
This result indicates that most of the transmission in the ﬁrst part
of the experiment occurred cell–cell.
To verify these results we analyzed cell-free and cell–cell
transmission in two additional ways. To conﬁrm the inhibitory
effects on cell-free transmission we co-transfected the conven-
tional single cycle reporter construct pCMVRU5-GFPluc, the
pCMVHT-1M packaging plasmid and increasing amounts of the
myc-tetherin construct, harvested the supernatants and trans-
ferred them to HeLa cells. The results of these experiments were
very similar to those obtained in the cell-free arm of the previous
experiments, in that we again saw a very steep decline in the
infectivity of the particles even with minimal tetherin input
(Fig. 3C, left panel). Western blot analysis of the pelleted super-
natants from this experiment showed that the quantity of
particles released into the supernatant inversely correlated with
the amount of tetherin plasmid transfected (Fig. 3C, right panel).
Next, we used the Jurkat–Raji cell–cell transmission assay with
the replication dependent pCMVRU5-inluc vector system to
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previously shown that infection with HTLV-1 from the transfected
Jurkat cells to Raji cells is almost entirely dependent on cell–cell
transmission as Raji cells are almost completely refractory to
infection by cell-free virus and Jurkat cells are a poor target cell
for either mode of transmission (Mazurov et al., 2010). Again, we
transfected the retroviral vector plasmids with increasing
amounts of the tetherin plasmid and measured the cell–cell
transmission to Raji cells added 24 h later. As in the cell–cell
infection arm of the 293 T experiment, the impact of tetherin was
mild; the amount of tetherin that was sufﬁcient to reduce cell-
free infection tenfold, had almost no effect on cell–cell transmis-
sion (Fig. 3D, left panel). However, at the highest concentration of
tetherin we did observe a signiﬁcant drop of transmission of
HTLV-1.
We analyzed the consequences of tetherin expression on Gag
accumulation in supernatants and cell extracts by ELISA and found
that the amount of anti-p19 reactive material in the supernatant
declined sharply with the smallest addition of tetherin but remained
constant in the cell extracts (Fig. 3D, right panel).
To conﬁrm these results, we measured the effect of induction
of tetherin expression by interferon-a (IFN-a) treatment on
HTLV-1 transmission from Jurkat to Raji cells. Jurkat cells,
transfected with retroviral vector plasmids, were treated with
different concentrations of IFN-a, washed and mixed with Raji
target cells. Fig. 3E (right panel) shows that although the level of
the endogenous tetherin in the Jurkat cells increased several fold
in response to the IFN-a treatment, cell–cell transmission was
only decreased by 40–50% (Fig. 3E, left panel).
In summary, even small amounts of tetherin severely reduced
the release of virus particles from the surface of producer cells
and limited cell-free infectivity of HTLV-1, while cell-cell trans-
mission was signiﬁcantly less impacted.Fig. 3. Tetherin severely decreases cell-free transmission but not cell-to-cell
infection. (A) Cartoon showing the replication-dependent HTLV-1 reporter vector
pCMVRU5-inluc, which contains ﬁreﬂy luciferase (luc) expression cassette tran-
scribed in opposite orientation relative to the retroviral genomic RNA. The luc gene
is interrupted by a DNA sequence that functions as an intron on the retroviral
vector transcript, but has no functionality on the luc mRNA. Thus, transcription,
splicing, packaging, infection, reverse transcription and integration are required to
generate an uninterrupted luc gene. (B) HEK293T cells were transfected with
HTLV-1 packaging plasmid pCMVHT1-M, pCMVRU5-inluc reporter vector and the
indicated amounts of plasmid expressing WT tetherin. After 24 h the media were
changed, after additional 24 h the supernatants were collected and the cells were
lysed. Luciferase activity in the cell lysate was determined as a measure of total
transmission in this culture (black line). The supernatants were transferred to
fresh HEK293T cells to measure the amount cell-free infectious virus. The cultures
were lysed 48 h after infection and luciferase activity was measured (gray line).
X-axis represents the amount of transfected tetherin plasmid (mg). Y-axis repre-
sents the relative infectivity, where 100% is viral transmission in the absence of
transfected tetherin. (C) Cell-free infectivity assay. Left panel: HEK293T cells were
transfected with 1 mg HTLV-1 packaging plasmid, 3 mg pCMVRU5-GFPluc reporter
vector and the indicated amounts of plasmid expressing WT tetherin. After 48 h,
media were collected and transferred to HeLa cells. The HeLa cells were lysed after
48 h and luciferase activity was determined as a measure of infection. The relative
level of infection is shown. Right panel: Western blot analysis of Gag expressed in
the cells (Gag p55) and released into supernatant (MA p19). (D) Cell-to-cell
transmission assay. Left panel: Jurkat cells were transfected with 1 mg HTLV-1
packaging plasmid pCMVHT1-M, 1.2 mg pCMVRU5-inluc reporter vector and plasmid
expressing WT tetherin. After 24 h, Jurkat cells were washed and mixed with
Raji cells and cells incubated for an additional 48 h. Luciferase activity was determined
as a measure of infection. X-axis represents the amount of transfected tetherin plasmid
(mg). Y-axis represents the results infectivity, where 100% is viral transmission in the
absence of transfected tetherin. Right panel: ELISA analysis of the amount of Gag
present in the Jurkat cells and released into the supernatant. (E) Left panel: Jurkat cells
transfected with HTLV-1 packaging plasmid pCMVHT1-M and pCMVRU5-inluc repor-
ter vector were treated with IFN-a for 24 h, thenwashed andmixed with Raji cells. The
results of cell-to-cell transmission assay were measured in 48 h. Right panel: The
increase of tetherin expression in Jurkat cells after IFN-a treatment was conﬁrmed by
western blot. Cell lysates were probed with anti-tetherin antibodies.Tetherin does not facilitate cell–cell transmission
Several previous reports have shown that HTLV-1 buds in a
polarized fashion (reviewed in Nejmeddine and Bangham, 2010)
and virus release is redirected to the cell–cell contact area after
interaction with the target cell. We tested whether tetherin and viral
proteins are polarized to the site of cell–cell contact by immuno-
ﬂuorescence. As reported before (Pais-Correia et al., 2010), we also
observed the colocalization of Gag and tetherin by immunoﬂuores-
cence and saw the apparent polarization of both Gag and tetherin to
the site of cell–cell contact (Fig. 4). We hypothesized that rather than
inhibiting cell–cell transmission of HTLV-1, tetherin actually
enhances it based on this evidence and the following ﬁndings:
(1) exogenous tetherin only marginally restricted cell-cell transmis-
sion even in Jurkat cells, which normally express tetherin; (2) the
study by Pais-Correia et al. (2010) showed that tetherin is part of a
bioﬁlm like structure that enhances HTLV-1 transmission, (3) as
shown above, HTLV-1 infected cells have higher than normal tetherin
levels (Figs. 2 and 4) the gradual decrease of cell–cell infection
observed in our experimental models was probably due to the
overexpression of tetherin (beyond physiological level). If the hypoth-
esis were true, then the tetherin expressed in Jurkat cells should
support HTLV-1 transmission, and silencing it with shRNA should
reduce cell–cell transmission. We generated pools of KD-tetherin
Fig. 4. Tetherin and Gag colocalize in the cell–cell contact area. Jurkat cells were loaded with calcein-blue (CB), mixed with MS9 cells and incubated for 30 min. Cells were
adhered to poly-Lysine coated slides, ﬁxed, permeabilized and probed with anti-tetherin and anti-p19MA antibodies.
Fig. 5. Silencing of tetherin facilitates cell-to-cell transmission. (A) Flow cytometry analysis of tetherin expression on the surface of Jurkat cell and Jurkat cells with shRNA
silencing of tetherin. (B) Cell-to-cell infectivity assay. Jurkat cells or Jurkat-shRNA(tetherin) cells were used as producer cells in cell-to-cell infectivity assay (for detail
description cell-to-cell infectivity assay see Material and Method). Y-axis represents the results infectivity, where 100% is viral transmission in Jurkat cells.
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marker and either a control shRNA sequence or shRNAs targeting
different sequences in the tetherin gene. Following selection for
puromycin resistance, knockdown of tetherin was evaluated based
on the surface expression of tetherin by FACS analysis. We identiﬁed
cell pools derived from two shRNAs sequences that had at least a
tenfold reduction of tetherin expression and we used these cells to
measure the effect of tetherin knock down on cell–cell transmis-
sion (Fig. 5A). The Jurkat-KD-tetherin cells showed a slight increase
(42%) in HTLV-1 transmission to Raji cells indicating that tetherin
has a small inhibitory effect on cell–cell transmission (Fig. 5B).
While there is a component of cell-free transmission even in this
system, it is less than 10% of the total infection (Mazurov et al.,
2010).Discussion
Eukaryotic cells have evolved a variety of innate mechanisms
to inhibit virus replication. Viruses that have successfully estab-
lished themselves in a given host species, have acquired ways to
overcome these host defenses. The recently discovered tetherin is
a restriction factor that prevents release of mature particles of a
variety of enveloped virus species and belongs to the cellular
defense system. One hallmark, which identiﬁes a cellular compo-
nent as a viral restriction factor, is that viruses evolve functions to
counteract it.
In this study, we set out to address the question whether
HTLV-1 has evolved a way to overcome the tetherin barrier. We
did not ﬁnd evidence for any tetherin antagonist that acts in a
fashion comparable to Vpu, Nef or Env in the different lenti-
viruses. Previous studies have shown that HTLV-1 Gag VLPs aresusceptible to retention on the cell surface (Jouvenet et al., 2009)
and we found that cell-free transmission of infectious virus in
in vitro assay systems is also severely restricted. However, most
retroviruses have been shown to be signiﬁcantly more infectious
when transmission can occur cell–cell rather than cell-free. This is
especially the case for HTLV-1, whose epidemiological proﬁle
suggests that cell-free transmission is all but impossible in vivo.
Several modes of cell–cell transmission with different retro-
viruses have been described based on microscopical observation
and a priori it is not clear whether tetherin would interfere with
this mode of transmission or actually enhance it.
Transmission of a retrovirus through the VS was ﬁrst described
for HTLV-1 (Igakura et al., 2003) and later also demonstrated to
occur with other retroviruses (Jolly et al., 2004). The VS is a relative
tight juxtaposition of the membranes of the effector and the target
cells initiated by the binding between Env and the receptor along
with engagement of ICAM-1 and LFA-1, respectively. The tight space
between the two cells is barely wide enough to accommodate one
particle (Jolly et al., 2004) easily allowing the particle budding from
the producer cell to reach and fuse with the target cell (Hubner
et al., 2009; Nejmeddine et al., 2009). Tetherin should only inhibit
this mode of transmission, if the tetherin molecules on the viral
particles posed a hindrance to fusion. In addition to the VS, which
involves a relatively large area of cell surface, transmission via
contacts at the end of membrane nanotubes involving similar but
signiﬁcantly smaller areas has been described. The HTLV-1 accessory
protein p8 has been reported to induce this type of structures (Van
Prooyen et al., 2011). Viruses are thought to move along these
nanotubes until they encounter the target cell. It is not clear
whether tetherin would impede this movement.
Recently, a report by Pais-Correia et al. (2010) suggested that
for HTLV-1 the adherence between cells only serves to keep the
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viral assemblies from the donor to the target cell. Viral assemblies
are the consequence of the polarized release of viruses, which are
caught up in a bioﬁlm-like network of glycosylated proteins.
Tetherin is one component of these glycosylated proteins in viral
assemblies, which enhance the infectivity of the virus mainly due
to the delivery of a high dose of virus at a time.
Three studies have evaluated the effect of tetherin on cell–cell
transmission of Vpu deﬁcient HIV-1; two groups reported relatively
small inhibitory effects of tetherin on cell–cell transmission (20 to
50%) (Casartelli et al., 2010; Kuhl et al., 2010), while the third group
observed an about twofold increase in the presence of tetherin (Jolly
et al., 2010). Although somewhat contradictory, taken together the
three studies show that the effect of tetherin on cell–cell transmission
of HIV-1 is signiﬁcantly less profound than on cell-free transmission.
Our results also suggest that the impact of tetherin on HTLV-1
cell–cell transmission in our Jurkat–Raji system is relatively
small. Cell–cell transmission is reduced less that twofold at low
and intermediated concentrations of tetherin that are sufﬁcient to
inhibit cell-free transmission more than twentyfold. Furthermore,
we saw a modest increase (42%) in cell–cell infection after knock
down of tetherin in Jurkat cells indicating that tetherin has a
small inhibitory effect. Conversely, we saw only twofold or lower
inhibition after introducing low to moderate amounts of exogen-
ous tetherin by transfection or after inducing the expression of
endogenous tetherin by IFN-a treatment; only high overexpres-
sion of tetherin resulted in a pronounced drop in cell–cell
transmission. While we are able to measure cell–cell transmission
accurately, our system is limited by the effector and target cells
that function in our assay (Mazurov et al., 2010). However, it
seems clear that, at least in this system, tetherin in the context of
viral assemblies does not contribute a beneﬁcial effect.
The interplay of the innate cellular immunity and HTLV-1 is
complex and not well understood yet (Journo and Mahieux, 2011).
While there is evidence that the system is activated in chronically
infected lines based on elevated expression of IFN-g (Smith et al.,
1999), it is also documented that Tax and HBZ deregulate the
signaling pathways of cellular immunity (Charoenthongtrakul et al.,
2011; Mukai and Ohshima, 2011). We found that tetherin expression
and cell surface presentation were signiﬁcantly higher in chronically
infected T-cell lines than in uninfected transformed CD4þ T-cell lines
or CD3/28 stimulated PBLs. This was not caused by higher levels of
IFN-a in the infected cells, as all cell lines expressed comparable and
very low levels of IFN-a (data not shown). However, recent studies by
Bego et al. (2012) showed that the tetherin gene BST2, like the IFN-a
genes, is activated as part of the early intrinsic immune response and
its expression can be maintained in the absence of IFN-a. Thus it
seems likely that chronically infected cells express elevated levels of
tetherin unless the virus is able to induce its downregulation. Even
for HIV-1, higher levels of tetherin in chronically infected than in
noninfected cells have been reported (Homann et al., 2011).
Recent studies by Tattermusch et al. (2012) demonstrated that
IFN-1 inducible genes are more highly transcribed in the white
blood cells of patients with HAM/TSP and that the level of
induction of these genes is highly correlated with the severity
of the disease. Although the upregulation of these genes was more
pronounced in monocytes and neutrophils than in CD4þ or CD8þ
T-lymphocytes in the patients, the CD4þ cells displayed expres-
sion markers indicating an activated state of intrinsic immune
response suggesting that BST2 would also be partially activated in
these cells as part of the intrinsic immune response.
Conclusion
We have found that tetherin in concentrations that severely
restricted release of HTLV-1 particles caused a slight inhibition onHTLV-1 cell–cell transmission, which is the major mode of HTLV-1
infection.Materials and methods
Cell culture
Human kidney HEK293T cells and human cervical carcinoma
HeLa cell lines were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum and
L-glutamine. Human Jurkat E6–1 cells (obtained from the Amer-
ican Type Culture Collection and the AIDS Research and Reference
Reagent Program, respectively) and Raji/CD4 cells (provided by
Vineet N. KewalRamani, NCI) were grown in RPMI-1640 medium
containing 10% fetal bovine serum and L-glutamine. The HTLV-1
immortalized cell lines MS9 and MS64 were obtained by co-
culture of activated human peripheral blood mononuclear cells
with HEK293T cells transfected with the HTLV-1 provirus clone
pHTLV-X1MT (Shuh et al., 1999) were maintained in RPMI-1640
medium supplemented with 15% fetal bovine serum, L-glutamine
and 100 U/ml recombinant interleukin 2 (IL-2). Cell lines HuT102,
MT2, C8166, cl3669 and Su68 have previously been described
(Mitchell et al., 2007). The following cell lines were obtained from
the AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH: MT2 (cat #237) from Dr D. Richman, C8166 (cat
#404) and H9 (cat#87) from Dr. R. Gallo, HUT78 (cat #87) from
Dr. A. Gazdar and Dr. R. Gallo. HUT 102 is described elsewhere
(Poiesz et al., 1980a). Peripheral blood lymphocytes (PBL) were
prepared from elutriated lymphocytes and stimulated with agar-
ose beads coated with anti-CD3 and anti-CD28 antibodies (Life-
Technologies) as described by the manufacturer and cultured for
7–10 days prior to harvest.
Plasmids
The HTLV-1 packaging plasmid pCMVHT1-M expresses all HTLV-1
gene products and has been described. The HTLV-1 reporter plasmid
pCMVRU5-GFPluc (Derse et al., 2001; Hill et al., 2003), which was
used in cell-free infections, was derived from pHTC-GFPluc by joining
the CMV promoter to the RU5 region of the 50 LTR at the TATA box.
For single-cycle cell–cell infections, we created the reporter plasmid
pCMVRU5-inluc; the reporter cassette within pCMVRU5-GFPluc was
replaced with a cassette containing the CMV promoter, luc gene (with
g-globin intron), and TK polyA signal (Mazurov et al., 2010). The
CMV-inluc-TK polyA cassette is oriented in the opposite direction
relative to viral vector transcription, but the intron is oriented in the
sense direction. The Myc-tagged tetherin expression plasmid was
provided by Bieniasz (Neil et al., 2008; Perez-Caballero et al., 2009).
pcDNAVphu was obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH from Dr.
Stephan Bour and Dr. Klaus Strebel (Nguyen et al., 2004).
Transfections and immunoblotting
HEK293T cells (1.2106 cells per 60 mm dish) cells and HeLa
cells (1.5106 cells per 60 mm dish) were transfected using
TransITs-293 (MIRUS) and FuGene (Roche), respectively, accord-
ing to the manufacturers’ protocols. Media was changed after 6 h
and 24 h after transfection samples were collected. VLPs were
concentrated by ultracentrifugation, viral pellets were dissolved
in NUPAGE LDS sample buffer with reducing reagent (Invitrogen)
and heated for 7 min at 90 1C. Cells were lysed in TNT buffer
(1% Triton X-100, 10 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM
EDTA) for 1 h on ice and samples were prepared as for VLPs. Cell
and VLP extracts were fractioned by SDS-PAGE and transferred to
A. Ilinskaya et al. / Virology 436 (2013) 201–209 207Immobilon membrane. Equal loading of proteins was monitored
by staining the membranes with Ponceau S solution (Sigma) or
probing for tubulin (mAB anti-tubulin, Sigma). Blots were probed
with anti-HTLV1-p19MA from ZeptoMetrix Corporation, anti-Myc
(Cell Signaling Technology), anti-tetherin (AIDS reagent program)
or anti-tubulin (Sigma). Membranes were blocked with 5% nonfat
milk in PBS with 0.02% Tween (Sigma) (PBST), probed with
primary antibodies, washed with PBST and developed with HRP-
conjugated secondary antibodies (Cell Signaling). Blots were
washed again, and immunoreactive bands were detected with
ChemiGlow Reagent on an AlphaImager (Alpha Innotec); the
signal intensity was determined to to quantify protein levels.
Statistical analysis was done using Student’s T-test (one-tailed,
unequal variance).
Real-time PCR
Real-time PCR and analysis of cDNA ampliﬁcation products
were performed as previously described (Princler et al., 2003).
The primer sequences used were: TETH-F2 CACCATCAAGGCCAA-
CAG and TETH-R2 CCATCACAGTGTGGTTGC.
Infection assays
Single-cycle replication assays to quantify cell-free infection
with HTLV-1 vectors have been described previously (Derse et al.,
2007). Brieﬂy, cell-free infections were performed by transfecting
HEK293T cells with packaging plasmid (pCMVHT1-M), reporter
plasmid (pCMVRU5 inluc or pCMVRU5-GFPluc), and tetherin
expression plasmid. Twenty four hours after transfection media
were changed and after additional 24 h the supernatants were
ﬁltered, added to 293 T or HeLa cells, respectively, and luciferase
activity was measured 48 h later using Promega BrightGlo luci-
ferase reagent and Lumat LB9501 luminometer (Berthold). Cell–
cell infections were performed by transfecting Jurkat cells
(2106 cells/well in a 12-well plate) with pCMVHT1-M packa-
ging vector, pCMVRU5-inluc reporter vector, and tetherin expres-
sion plasmid using TransITs-Jurkat (Mirus) transfection reagent.
The following day, cells were washed with PBS and mixed with an
equal number of Raji-CD4þ cells in complete RPMI. After 48 h
cells were collected, lysed and luciferase activity was measured as
above. For one-step infection assays (combined cell-free and cell–
cell) HEK293T cells were transfected with pCMVHT1-M packaging
vector, pCMVRU5-inluc reporter vector, and tetherin expression
plasmid. Media were changed after 24 h and after additional 24 h
cells were collected and lysed after 48 h; luciferase activity was
determined as above.
shRNA silencing
shRNAs (Openbiosystem, cat number: RHS4533, clones
TRCN0000107019 and TRCN0000107018) directed against the
tetherin/BST2 were used to silence tetherin in Jurkat cells. shRNA
was delivered to Jurkat cells through lentivirus infection accord-
ing the manufacturer’s protocol. Puromycin (2 mg/ml) was used
for selection.
FACS analysis of tetherin surface expression
Jurkat cells were collected and probed with anti-tetherin antibody
(obtained from the AIDS Research and Reference Reagent Program,
NIH, cat# 11722 from Drs. Klaus Strebel and Amy Andrew) in PBS
containing 1% BSA on ice. Goat anti-rabbit IgG-PE (BD) was used as
secondary antibody. Samples were analyzed on a FACS Calibur (BD).Confocal microscopy
Jurkat cells (1106) were stained with calcein blue (Molecular
Probes) according a manufactured protocol and mixed with MS9
cells. After 30 min, cells were seeded on polylysine coated cover
slips for additional 30 min. Cells were ﬁxed with 2% paraformal-
dehyde, and incubated with rabbit anti-tetherin antibody
(obtained from the AIDS Research and Reference Reagent Pro-
gram, NIH) in PBS containing 1% BSA. Goat anti-rabbit antibody
conjugated with Alexa Fluor 488 was used for staining. Cells were
permeabelized and probed with anti-p19MA (ZeptoMetrix
Corporation) antibody. Alexa Fluor 594—conjugated anti-mouse
antibody was used for staining. Slides were maintained in Pro-
Long Antifade reagent and analyzed on a Zeiss LSM 510 Inverted
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